natgillin/translations-raw huggingface dataset:
An increase in pneumonia has been observed in patients with COPD receiving fluticasone furoate/vilanterol.
U bolesnika s KOPB-om liječenih flutikazonfuroatom/vilanterolom zabilježena je povećana incidencija pneumonije.
an increase in protein in the urine, an increase in cholesterol in the blood, and swelling from excess fluid (oedema) (also called ‘nephrotic syndrome’) blood clot in very small blood vessels (also called ‘thrombotic microangiopathy’).
povišene vrijednosti proteina u mokraći, povišene vrijednosti kolesterola u krvi i oticanje zbog prekomjerne količine tekućine (edem) (poznato i kao ‘nefrotski sindrom’) krvni ugrušak u vrlo malim krvnim žilama (poznato i kao ‘trombotička mikroangiopatija’).
an increase in some liver enzymes an increase in bilirubin, a breakdown product of red blood cells, which can cause yellowing of the skin and eyes.
povišene vrijednosti nekih jetrenih enzima povišene vrijednosti bilirubina, koji nastaje razgradnjom crvenih krvnih stanica i zbog kojeg koža i oči mogu poprimiti žutu boju.
an increase in some liver results which may develop into serious conditions such as hepatitis and jaundice,
porast jetrenih enzima što se može razviti u ozbiljno stanje poput hepatitisa i žutice,
an increase in some liver results which may develop into serious conditions such as hepatitis and jaundice,
porast vrijednosti određenih jetrenih enzima koji može dovesti do ozbiljnih stanja poput hepatitisa i žutice,
an increase in some liver results which may develop into serious conditions such as hepatitis and jaundice,
povećanje rezultata u rezultatima nekih jetrenih testova što se može razviti u ozbiljna stanja poput hepatitisa i žutice,
an increase in some liver test results,
porast vrijednosti određenih jetrenih enzima,
An increase in some liver test results. problems in the nerves of the arms or legs (peripheral neuropathy).
porast vrijednosti određenih jetrenih enzima; problemi sa živcima u rukama ili nogama (periferna neuropatija).
An increase in still-born pups and decrease in post-natal viability of pups was observed in pre- postnatal toxicity studies in rats.
Opaženo je povećanje broja mrtvorođene mladunčadi i smanjenje postnatalne životne aktivnosti u pre- postnatalnim ispitivanjima toksičnosti u štakora.
an increase in sugar (glucose) in the blood an increase in triglycerides (type of fat) in the blood
povećanje razine šećera (glukoze) u krvi povećanje razine triglicerida (jedne vrste masnoće) u krvi.
an increase in the amount of potassium in the blood changes in the rhythm of the heart, or the heart beating faster than normal
povećana razina kalija u krvi promjene srčanog ritma ili srce kuca brže nego obično
An increase in the amount of sugar (glucose) in your blood.
Povišena razina šećera (glukoze) u krvi.
An increase in the concentration of enoxaparin sodium after using prophylactic doses (non-weight adjusted) has been observed in low-weight female patients (<45 kg) and low-weight male patients (<57 kg), which may lead to a higher risk of bleeding.
Primijećen je porast koncentracije enokaparin-natrija nakon primjene profilaktičkih doza (bez prilagodbe prema TT) u bolesnica niske tjelesne težine (<45 kg) i muških bolesnika niske tjelesne težine (<57 kg), koja bi mogla dovesti do povišenog rizika za nastanak krvarenja.
An increase in the concentration of enoxaparin sodium after using prophylactic doses (non-weight adjusted) has been observed in low-weight female patients (<45 kg) and low-weight male patients (<57 kg), which may lead to a higher risk of bleeding.
Primijećen je porast koncentracije enokaparin-natrija nakon primjene profilaktičkih doza (bez prilagodbe prema TT) u bolesnica niske tjelesne težine (>45 kg) i muških bolesnika niske tjelesne težine (<57 kg), koja bi mogla dovesti do povišenog rizika za nastanak krvarenja.
An increase in the concentration of enoxaparin sodium after using prophylactic doses (non-weight adjusted) has been observed in low-weight female patients (<45 kg) and low-weight male patients (<57 kg), which may lead to a higher risk of bleeding.
Primijećen je porast koncentracije enokaparinnatrija nakon primjene profilaktičkih doza (bez prilagodbe prema TT) u bolesnica niske tjelesne težine (< 45 kg) i muških bolesnika niske tjelesne težine (< 57 kg), koja bi mogla dovesti do povišenog rizika za nastanak krvarenja.
An increase in the dose of a particular blood-thinning medicine (heparin) during haemodialysis is often needed during the course of therapy with Retacrit to minimize the risk of blood clotting.
Za vrijeme terapije Retacritom često je potrebno povećanje doze posebnih lijekova za razrjeđivanje krvi (heparin) tijekom hemodijalize da bi se smanjio rizik zgrušavanja krvi.
An increase in the dose of a particular blood-thinning medicine (heparin) during haemodialysis is often needed during the course of therapy with Silapo to minimize the risk of blood clotting.
Za vrijeme terapije Silapom često je potrebno povećanje doze posebnih lijekova za razrjeđivanje krvi (heparin) tijekom hemodijalize da bi se smanjio rizik zgrušavanja krvi.
An increase in the dose of lopinavir/ritonavir to 533/133 mg (4 capsules) or 500/125 mg (5 tablets with 100/25 mg each) twice daily with food is recommended in combination with Nevirapine Teva.
Povišenje doze lopinavir/ritonavira na 533/133 mg (4 kapsule) ili 500/125 mg (5 tableta s 100/25 mg svaka) dvaput dnevno s hranom preporučuje se u kombinaciji s Nevirapinom Teva.
An increase in the incidence in trazodone- related adverse events was noted when coadministered with ritonavir.
Kod istodobne primjene s ritonavirom primijećeno je povećanje incidencije nuspojava povezanih s trazodonom.
An increase in the incidence in trazodone-related adverse reactions was noted when co-administered with ritonavir dosed as an antiretroviral agent or as a pharmacokinetic enhancer.
Pri primjeni trazodona istodobno s ritonavirom kao antiretrovirusnim lijekom ili kao farmakokinetičkim pojačivačem zabilježena je povećana učestalost nuspojava povezanih s trazodonom .
An increase in the incidence in trazodone-related adverse reactions was noted when co-administered with ritonavir dosed as an antiretroviral agent or as a pharmacokinetic enhancer.
Pri primjeni trazodona istodobno s ritonavirom kao antiretrovirusnim lijekom ili kao farmakokinetičkim pojačivačem zabilježena je povećana učestalost nuspojava povezanih s trazodonom.
an increase in the level of liver enzymes a decrease in the number of cells involved in blood clotting (thrombocytopenia).
porast razine jetrenih enzima smanjenje broja trombocita, krvnih pločica važnih za zgrušavanje krvi (trombocitopenija).
an increase in the level of liver enzymes an increased amount in the blood of bilirubin (a substance produced in the liver) which may make your skin appear yellow
porast razine jetrenih enzima povišena razina bilirubina (tvari koja se stvara u jetri) u krvi zbog koje Vam koža može izgledati žuta.
an increase in the level of liver enzymes an increased amount in the blood of bilirubin (a substance produced in the liver) which may make your skin appear yellow.
porast razine jetrenih enzima povišenje razine bilirubina (tvar koja se proizvodi u jetri) u krvi što može činiti Vašu kožu žutom.
an increase in the level of liver enzymes an increased amount in the blood of bilirubin (a substance produced in the liver) which may make your skin appear yellow.
porast razine jetrenih enzima povišenje razine bilirubina (tvar koja se stvara u jetri) u krvi što može činiti Vašu kožu žutom.
an increase in the levels of fat in the blood (cholesterol and triglycerides), a decrease in the levels of phosphate in the blood.
povećanje razine masnoća u krvi (kolesterol i trigliceridi), smanjenje razine fosfata u krvi.
An increase in the levels of fat in the blood (cholesterol and triglycerides).
povećanje razine masnoća u krvi (kolesterol i trigliceridi);
An increase in the number of blood cells called eosinophiles (eosinophilia).
povećanje broja krvnih stanica koje se zovu eozinofili (eozinofilija);
An increase in the number of blood cells called eosinophiles (eosinophilia).
povećanje broja krvnih stanica koji se zovu eozinofili (eozinofilija);
an increase in the number or proportion of white blood cells shown in blood tests
povećanje broja ili udjela bijelih krvnih stanica što se vidi u krvnim pretragama
an increase in the numbers of blood cells called eosinophiles (eosinophilia); mild decrease in the number of white blood cells (leucopenia); decrease in the number of all blood cells (pancytopenia),
porast broja krvnih stanica zvanih eozinofili (eozinofilija), blagi pad broja bijelih krvnih stanica (leukopenija); pad broja svih krvnih stanica (pancitopenija),
an increase in the numbers of blood cells called eosinophiles (eosinophilia); mild decrease in the number of white blood cells (leucopenia); decrease in the number of all blood cells (pancytopenia),
porast broja krvnih stanica zvanih eozinofili (eozinofilija), blago smanjenje broja bijelih krvnih stanica (leukopenija), smanjenje broja svih krvnih stanica (pancitopenija),
an increase in the numbers of blood cells called eosinophiles (eosinophilia); mild decrease in the number of white blood cells (leucopenia); decrease in the number of all blood cells (pancytopenia),
povećanje broja krvnih stanica koje se zovu eozinofili (eozinofilija); blago smanjenje broja bijelih krvnih stanica (leukopenija); smanjenje broja svih krvnih stanica (pancitopenija),
An increase in the occurrence of blood clots has been observed.
Primijećena je povećana pojava krvnih ugrušaka
An increase in the occurrence of blood clots has been observed.
Primijećena je povećana pojava krvnih ugrušaka.
an increase in the thickness in the mouth or tongue;
zadebljanje usne šupljine ili jezika;
An increase in uric acid and indirect bilirubin values associated with haemolysis was observed in some patients treated with ribavirin used in combination with peginterferon alfa-2b or interferon alfa- 2b in clinical trials, but values returned to baseline levels by four weeks after the end of therapy.
U nekih bolesnika liječenih ribavirinom u kombinaciji s peginterferonom alfa-2b ili interferonom alfa-2b u kliničkim ispitivanjima primijećeno je povišenje vrijednosti mokraćne kiseline i indirektnog bilirubina povezano s hemolizom, no te su se vrijednosti vratile na početne najkasnije 4 tjedna po završetku liječenja.
An increase in weight and in levels of blood lipids and glucose may occur during antiretroviral theraphy.
Povećanje tjelesne težine i razine lipida i glukoze u krvi mogu se pojaviti tijekom antiretrovirusne terapije.
An increase in weight and in levels of blood lipids and glucose may occur during antiretroviral therapy.
Povećanje tjelesne teţine i razina lipida i glukoze u krvi mogu se pojaviti tijekom antiretrovirusne terapije.
An increase in weight and in levels of blood lipids and glucose may occur during antiretroviral therapy.
Tijekom antiretrovirusne terapije može doći do povećanja tjelesne težine te razina lipida i glukoze u krvi.
An increase in your serum creatinine level (problems with your kidneys),
povećanje razine kreatinina u serumu (tegobe s bubrezima),
an increase in your weight blood pressure dropping upon your standing up which may cause fainting.
ako dobijete na težini ako Vam pri ustajanju pada krvani tlak, što može izazvati nesvjesticu.
An increase of blood pressure, bradycardia or tachycardia and limb or back pain might be possible.
Mogući su povišeni krvni tlak, bradikardija, tahikardija te bolovi u udovima ili leđima.
an increase of certain enzymes in the blood (creatine phosphokinase), problems in the nerves of the arms or legs (peripheral neuropathy).
porast koncentracije određenih enzima u krvi (kreatin fosfokinaze), problemi sa živcima u rukama ili nogama (periferna neuropatija).
An increase of certain enzymes in the blood (creatine phosphokinase).
porast koncentracije određenih enzima u krvi (kreatin fosfokinaze);
an increase of certain enzymes in theblood (creatinephosphokinase), problems in the nerves of the arms or legs (peripheral neuropathy).
porast koncentracije određenih enzima u krvi (kreatin fosfokinaze), problemi sa živcima u rukama ili nogama (periferna neuropatija).
An increase of frequency and severity of some adverse reactions was observed, mainly diarrhoea and skin rash.
Opažena je povećana učestalost i težina nekih nuspojava, uglavnom proljeva i osipa kože.
an increase of Kaletra dosage may
lijek Kaletra i započinju uzimanje
An increase of lactate dehydrogenase (a blood enzyme).
povećanje enzima laktat dehidrogenaze u krvi;
An increase of non- Hodgkin’s lymphoma growth was noted after a continuous administration of plerixafor for 28 days.
Nakon kontinuirane primjene pleriksafora tijekom 28 dana zabilježeno je povećanje rasta ne-Hodgkinova limfoma.
An increase of second primary malignancies (SPM) has been observed in clinical trials in previously treated myeloma patients receiving lenalidomide/dexamethasone (3.98 per 100 person-years) compared to controls (1.38 per 100 person-years).
Porast drugih primarnih malignih bolesti primijećen je u kliničkim ispitivanjima prethodno liječenih bolesnika s mijelomom koji su primali lenalidomid/deksametazon (3,98 na 100 osoba-godina) u usporedbi s kontrolnim skupinama (1,38 na 100 osoba-godina).
An increase of the simvastatin dose may be required when used concomitantly with eslicarbazepine acetate.
Povećanje doze simvastatina može biti potrebno, ukoliko se koristi istodobno s eslikarbazepinacetatom.
An increase of ≥1 g/dL change in Hb at Week 12 was achieved in 90 % and 69 % of the ulcerative colitis (N=29) and Crohn’s Disease (N=35) subgroups, respectively.
Povećanje od ≥ 1 g/dL promjene u razini Hb-a u 12. tjednu postignuto je kod 90 % bolesnika iz podskupine bolesnika koji boluju od ulceroznog kolitisa (N = 29) i 69 % bolesnika iz podskupine bolesnika koji boluju od Kronove bolesti (N = 35).
An increase of ≥2 g/dL change in Hb at Week 12 was achieved in 62 % and 51 % of the ulcerative colitis and Crohn’s Disease subgroups, respectively.
Povećanje od ≥ 2 g/dL promjene u razini Hb-a u 12. tjednu postignuto je kod 62 % bolesnika iz podskupine bolesnika koji boluju od ulceroznog kolitisa i 51 % bolesnika iz podskupine bolesnika koji boluju od Kronove bolesti.
An increased 3H-thymidine incorporation in the erythroid nucleated spleen cells has been found in vitro (mouse spleen cell culture) after incubation with erythropoietin.
In vitro (kultura stanica slezene miševa) je nađena povećana ugradnja 3H-timidina u eritroidne stanice slezene nakon inkubacije eritropoetinom.
An increased dose (1,000 mg TID) of indinavir does not compensate for the inducing effect of efavirenz.
Povećana doza indinavira (1000 mg TID) ne kompenzira induktivno djelovanje efavirenza.
An increased dose of theophyline may be required when co-administered with ritonavir, due to induction of CYP1A2.
Zbog indukcije CYP1A2 može biti potrebno povećanje doze teofilina kada ga se daje istodobno s ritonavirom.
An increased drug half-life has been observed in patients with severe hepatic impairment, possibly related to increased tissue distribution.
Produljeni poluvijek lijeka koji je bio zabilježen kod bolesnika s teškim oštećenjem funkcije jetre, može biti povezan s povećanom distribucijom u tkiva.
An increased drug half-life has however been observed in patients with severe hepatic impairment (see section 4.4 and 5.2).
Produljeni poluvijek lijeka bio je zabilježen kod bolesnika s teškim oštećenjem jetre. (vidjeti dio 4.4 i 5.2).
An increased frequency was noted when given as add-on to metformin and a sulfonylurea (empagliflozin 10 mg: 16.1%, empagliflozin 25 mg: 11.5%, placebo: 8.4%), and as add-on to insulin with or without metformin and with or without a sulphonylurea (empagliflozin 10 mg: 19.5%, empagliflozin 25 mg: 27.1%, placebo: 20.6% during initial 18 weeks treatment when insulin could not be adjusted; empagliflozin 10 mg: 36.1%, empagliflozin 25 mg: 34.8%, placebo 35.3% over the 78-week trial).
Povećana učestalost je zabilježena kada je lijek primjenjivan kao dodatak uz metformin i sulfonilureju (empagliflozin 10 mg: 16,1%, empagliflozin 25 mg: 11,5%, placebo: 8,4%) i kao dodatak uz inzulin sa ili bez metformina te sa ili bez sulfonilureje (empagliflozin 10 mg: 19,5%, empagliflozin 25 mg: 27,1%, placebo: 20,6% tijekom početnih 18 tjedana liječenja kada se doza inzulina nije mogla prilagođavati; empagliflozin 10 mg: 36,1%, empagliflozin 25 mg: 34,8%, placebo 35,3% tijekom 78-tjednog ispitivanja).
An increased incidence and severity of renal tubular basophilia/hyalinisation, dilation and casts, as well as interstitial lymphocyte inflammation and arteriolar medial hypertrophy were found at an exposure of 8–13 (valsartan) and 7–8 (amlodipine) times the clinical doses of 160 mg valsartan and 10 mg amlodipine.
Nađena je povećana incidencija i težina bazofilije/hijalinizacije bubrežnih tubula, dilatacija i odljeva, kao i intersticijska limfocitna upala te medijalna hipertrofija arteriola pri izloženosti 8–13 (valsartan) i 7–8 (amlodipin) puta višim od izloženosti kliničkim dozama od 160 mg valsartana i 10 mg amlodipina.
An increased incidence in bone fractures in women was seen in a pooled analysis of adverse reactions of bone fracture from randomised, controlled, double blind clinical trials in over 8100 pioglitazone and 7400 comparator treated patients, on treatment for up to 3.5 years.
Povećana incidencija prijeloma kostiju u žena opažena je u analizi objedinjenih podataka o prijelomima kostiju kao nuspojava u randomiziranim, kontroliranim, dvostruko slijepim kliničkim ispitivanjima na više od 8100 bolesnika liječenih pioglitazonom i 7400 bolesnika liječenih usporednim lijekovima u trajanju do najviše 3,5 godine.
An increased incidence in bone fractures in women was seen in a pooled analysis of adverse reactions of bone fracture from randomised, controlled, double-blind clinical trials in over 8,100 pioglitazone- and 7,400 comparator-treated patients, on treatment for up to 3.5 years.
Povećana incidencija prijeloma kostiju u žena opažena je u analizi objedinjenih podataka o prijelomima kostiju kao nuspojave u randomiziranim, kontroliranim, dvostruko slijepim kliničkim ispitivanjima na više od 8100 bolesnika liječenih pioglitazonom i 7400 bolesnika liječenih usporednim lijekom u trajanju do 3,5 godine.
An increased incidence of adrenal medullary hyperplasia and pheochromocytoma was observed in male rats at doses of 1 mg/kg/day and above ( 1 times the clinical exposure with the maximum recommended human dose [MRHD] based on AUC) and female rats at all dose levels ( 0.3 times the clinical exposure with the MRHD based on AUC).
Povećana incidencija hiperplazije srži nadbubrežne žlijezde i feokromocitoma zabilježena je kod mužjaka štakora pri dozama od 1 mg/kg/dan i iznad ( 1 puta klinička izloženost s maksimalno dozvoljenom dozom kod ljudi temeljenoj na AUC) i ženkama štakora pri svim dozama ( 0,3 puta klinička izloženost s maksimalno dozvoljenom dozom kod ljudi temeljena na AUC).
An increased incidence of elevations of ALT or AST > 5 times the ULN was reported in Zinbryta-treated patients compared to placebo (4% versus <1%) or interferon beta-1a (intramuscular) (6% versus 3%).
Povećana incidencija povišenja razine ALT ili AST > 5 puta GGN prijavljena je u bolesnika liječenih Zinbrytom u usporedbi s placebom (4% naspram <1%) ili interferonom beta-1a (intramuskularno) (6% naspram 3%).
An increased incidence of embryo-loss has been observed in rabbits at high multiples of the clinical exposure and in the presence of maternal toxicity (see section 5.3)..
Povećana incidencija gubitaka embrija opažena je u kunića pri izloženosti višestruko većoj od kliničke izloženosti i u prisutnosti toksičnosti za majku (vidjeti dio 5.3).
An increased incidence of graft thrombosis was observed in the post-transplant period in recipients of extended criteria donor allografts (see section 4.8).
Povišena incidencija tromboze presatka primijećena je u primatelja u razdoblju nakon presađivanja alografta s darivatelja prema proširenim kriterijima (vidjeti dio 4.8).
An increased incidence of hypertension was observed in Avastin-treated patients.
U bolesnika liječenih lijekom Avastin opažena je veća incidencija hipertenzije.
An increased incidence of infections and serious infections was not observed in patients with lymphocyte counts <0.8x109/l or
Povećana incidencija infekcija i ozbiljnih infekcija nije zabilježena u bolesnika s brojem limfocita <0,8x109/l ili <0,5x109/l.
An increased incidence of keratoacanthoma in the skin was observed in male rats at doses of 4 and
Povećana incidencija keratoakantoma u koži zabilježena je u mužjaka štakora pri dozama od 4 i
An increased incidence of LVEF declines was also observed in patients treated with Perjeta in combination with trastuzumab and docetaxel; LVEF recovered to ≥50% in all patients.
U bolesnika liječenih lijekom Perjeta u kombinaciji s trastuzumabom i docetakselom primijećena je i povećana incidencija smanjenja ejekcijske frakcije lijeve klijetke; ejekcijska frakcija lijeve klijetke oporavila se na ≥50% u svih bolesnika.
An increased incidence of retinal atrophy commonly observed in aged albino rats was seen after long- term exposure to pregabalin at exposures ≥ 5 times the mean human exposure at the maximum recommended clinical dose.
Povećana incidencija atrofije mrežnice, uobičajene u starijih albino štakora, opažena je nakon dugotrajne izloženosti pregabalinu ≥ 5 puta veće od prosječne izloženosti u ljudi kod primjene najviše preporučene kliničke doze.
An increased incidence of retinal atrophy commonly observed in aged albino rats was seen after long-term exposure to pregabalin at exposures≥ 5 times the mean human exposure at the maximum recommended clinical dose.
Povećana incidencija atrofije mrežnice, uobičajene u starijih albino štakora, opažena je nakon dugotrajne izloženosti pregabalinu ≥ 5 puta veće od prosječne izloženosti u ljudi kod primjene najviše preporučene kliničke doze.
An increased incidence of thrombotic vascular events (see section 4.4 and section 4.8 - General) has been observed in patients receiving erythropoietic agents.
Povećana incidencija trombotičkih vaskularnih događaja (vidjeti dio 4.4 i dio 4.8 – opći) primijećena je kod bolesnika koji primaju eritropoetske pripravke.
An increased incidence of thrombotic vascular events (see section 4.4 and section 4.8 - General) has been observed in patients receiving erythropoietic agents.
Povećana incidencija trombotičkih vaskularnih događaja (vidjeti dio 4.4. i dio 4.8 – opći) primijećena je kod bolesnika koji primaju eritropoetske pripravke.
An increased infection rate and impairment of the immune response cannot be excluded.
Nije moguće isključiti povećanu stopu infekcija i poremećaj imunološkog odgovora.
An increased level of the enzyme that breaks down fats and of the enzyme that breaks down starch.
povišena razina enzima koji razgrađuje masnoće i enzima koji razgrađuje škrob
An increased relative risk for thromboembolic events was observed in the overall population (RR 1.62, 95% CI: 1.13, 2.31).
U ukupnoj populaciji primijećen je povećani relativni rizik od tromboembolijskih događaja (RR 1,62, 95% CI: 1,13; 2,31).
An increased relative risk of thromboembolic events (RR 1.67, 95% CI: 1.35, 2.06, 35 trials and 6 769 patients) was observed in patients treated with recombinant human erythropoietin.
Povećan relativni rizik od tromboembolijskih događaja (RR 1,67, 95% CI: 1,35, 2,06, 35 ispitivanja i 6 769 bolesnika) primijećen je kod bolesnika koji se liječe rekombinantnim humanim eritropoetinom.
An increased relative risk of thromboembolic events (RR 1.67, 95% CI: 1.35, 2.06; 35 trials and 6,769 patients) was observed in patients treated with recombinant human erythropoietin.
Povećan relativni rizik od tromboembolijskih događaja (RR 1,67, interval pouzdanosti 95%: 1,35, 2,06; 35 ispitivanja i 6769 bolesnika) zabilježen je u bolesnika liječenih rekombinantnim humanim eritropoetinom.
An increased risk of bleeding cannot be excluded in patients: with hereditary vitamin K dependent clotting factor deficiencies;
Ne može se isključiti povećan rizik od krvarenja u bolesnika: s nasljednim nedostatkom faktora zgrušavanja ovisnih o vitaminu K;